Drugs targeting TTR to inhibit amyloid deposition for treating fibrotic diseases have emerged, such as Tafamidis, which can bind to TTR and prevent tetramer dissociation and amyloidogenesis.[108] In the clinic, Tafamidis has been used to treat TTR amyloid cardiomyopathy,[109] but not LSS caused by LFH. The gene discussed is TTR; the disease is cardiac amyloidosis.